Search results for "FDG PET"
showing 10 items of 14 documents
Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT
2018
Objective:To investigate metabolic parameters as predictive of local response after stereotactic body radiation therapy (SBRT) for liver-oligometastases.Methods:Inclusion criteria of the present re...
Factor analysis-based approach for early uptake automatic quantification of breast cancer by 18F-FDG PET images sequence
2014
International audience; Factor Analysis of Medical Image Sequences (FAMIS) is recognized as one pioneer successfully used approach for analyzing especially dynamic images' sequence for estimating kinetics and associated compartments having a physiological meaning. Some studies tried to extend the exploring of this approach to analyze Positron Emission Tomography (PET) image modality for dynamic sequences. PET images with 18F-fluorodesoxyglucose (18F-FDG) is the gold standard for in vivo, evaluation of tumor glucose metabolism and is widely used in clinical oncology. In this paper, a novel approach is proposed to obtain an automated quantification method for early accumulation of 18F-FDG tra…
Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma
2018
Abstract BACKGROUND Although the overall prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) has improved, nearly a third of patients will have refractory disease or relapse. Identification of these high-risk patients using traditional prognostic factors is limited. PET is the recommended imaging modality for the staging of FDG-avid lymphoma but the value of a comprehensive new imaging biomarkers analysis applied to PET for the prediction of patients outcome has still not been deeply investigated. New metrics estimating the overall tumor burden such as metabolic tumor volume (MTV) and those that may capture intratumoral biological heterogeneity such as total lesion glycolysis…
Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria
2016
BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLCwere enrolled prospectively. PET/CT studies were performed before, then 48 hours, and 45 days after…
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
2007
To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR).Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships betwe…
Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis
2015
The purpose of this study was to evaluate the clinical value of PET (Positron Emission Tomography) for early prediction of tumor response to platinum-based therapy in patients with nonsmall cell lung cancer (NSCLC). The evaluation was carried out comparing the standard treatment response using RECIST (Response Evaluation Criteria in Solid Tumors) with metabolic treatment response according to European Organization for Research and Treatment of Cancer (EORTC) recommendations, PET Response Criteria in Solid Tumors (PERCIST), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). Seventeen inoperable patients with stage IV NSCLC were enrolled between October 2011 and June 2013: PET st…
Development of a gene panel for 18F-FDG PET positivity prediction in gastric cancer.
2020
420 Background: 18F-FDG PET is widely used in clinical cancer diagnostics. However, 18F-FDG PET scan in gastric cancer (GC) is still controversial because of its lower sensitivity in diagnosis and staging compared to other imaging modalities. The purpose of this study was to establish a gene panel for 18F-FDG PET positivity in GC by using patient-derived xenografts (PDXs). Methods: BALB/c nude mice were subcutaneously implanted with 30 cases of GC PDX tissues and underwent a simultaneous PET/MRI scanner. Using RNA-seq data of the 30 GC PDXs for training set, we constructed a gene co-expression network which was correlated with the maximal standardized uptake values (SUVmax). The least abso…
The role of 18F-FDG PET/CT in early infectious discitis: a case report after a negative MRI
2019
We present the case of a 70 years old woman with infectious discitis which was detected using Fluorine fluodeoxiglucose positron emission tomography/computed tomography (18F-FDG PET/CT), after a negative magnetic resonance imaging. A Streptococuss gallolyticus (bovis gender bacteria) grow on culture. In addition 18F-FDG PET also demonstrated infectious endocarditis which was confirmed by transesophageal echocardiography and a colonic neoplasm. Here we have highlighted the potential role of 18F-FDG PET/CT study in patients with a clinical history suggestive of infectious discitis with a negative or indifferent magnetic resonance imaging. Keywords: 18F-FDG PET/TC, Spondylodiscitis, Pyogenic v…
Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and …
2019
The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion c…
Utilidad del análisis de los parámetros metabólicos de la 18F-FDG PET/TC en pacientes con cáncer de mama. Valor añadido de la tomografía por emisión …
2019
UTILIDAD DEL ANÁLISIS DE LOS PARÁMETROS METABÓLICOS DE LA 18F-FDG PET-TC EN PACIENTES CON CÁNCER DE MAMA. VALOR AÑADIDO DE LA TOMOGRAFÍA POR EMISIÓN DE POSITRONES (MAMMI-PET) La hipótesis principal es que los parámetros metabólicos obtenidos de la 18F-FDG PET/TC (SUV máx, GTL y VMT) en pacientes con cáncer de mama podrían ser útiles en la valoración pronóstica dependiendo del perfil IHQ de los tumores. Objetivos secundarios: - Correlacionar parámetros metabólicos analizados con perfiles IHQ. - Correlacionar parámetros metabólicos con características clínico-tumorales (edad, tipo y grado histológico, localización y tamaño tumoral, actividad proliferativa ki67, expresión de receptores). - Cor…